# Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Study · id `cardio:ct-nct01774968` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01774968](<https://clinicaltrials.gov/study/NCT01774968>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01774968

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 325 participants.

## Technical summary

Registry record NCT01774968. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-05-12.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 325 participants (enrolled count; ClinicalTrials.gov record NCT01774968, source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)
- Start date: 2013-02 (registry gives no type) (ClinicalTrials.gov record NCT01774968, source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)
- Primary completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01774968, source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)
- Completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01774968, source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)
- Results first posted: 2015-05-12 (ClinicalTrials.gov record NCT01774968, source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT01774968, source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01774968-2015-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Human Regular U-500 Insulin
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL (`cardio:pubmed-25813411`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS (`cardio:pubmed-26307903`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial (`cardio:pubmed-27716283`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b99bf9b440b7d0770135148e7cf24063bf1df45f62f816e3fd94a5eb2e7854d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
